Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …

RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

Abstract Treatment options for patients with metastatic melanoma, and especially BRAF-
mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of …

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have recently
entered the therapeutic armamentarium of clinical oncologists, and show promising activity …

Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery
and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

Biochemical and genetic characterization of D-type cyclins, their cyclin D–dependent
kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16INK4 over two …